Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
A Phase I/II Study of Induction Chemotherapy With Daunorubicin, Cytarabine, Topotecan and Etoposide
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2012-09-25
- Target Recruit Count
- 41
- Registration Number
- NCT00005793
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 3
- Registration Number
- NCT00060385
- Locations
- 🇧🇪
U.Z. Gasthuisberg, Leuven, Belgium
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-30
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT00003436
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection
- Conditions
- First Posted Date
- 2003-04-23
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Centro di Riferimento Oncologico - Aviano
- Target Recruit Count
- 30
- Registration Number
- NCT00003262
- Locations
- 🇮🇹
Centro di Riferimento Oncologico - Aviano, Aviano, Italy
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-04-18
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 16
- Registration Number
- NCT00003597
- Locations
- 🇺🇸
Long Beach Memorial Medical Center, Long Beach, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
🇺🇸Herbert Irving Comprehensive Cancer Center, New York, New York, United States
Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 400
- Registration Number
- NCT00002822
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-16
- Last Posted Date
- 2012-04-13
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 61
- Registration Number
- NCT00002945
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 750
- Registration Number
- NCT00002701
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹Federico II University Medical School, Naples (Napoli), Italy
🇮🇹Ospedale S. Gennora USL 42, Naples (Napoli), Italy
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-10
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT00002658
- Locations
- 🇬🇧
University of Wales College of Medicine, Cardiff, Wales, United Kingdom
Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-04-10
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 429
- Registration Number
- NCT00002550
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸Veterans Affairs Medical Center - Indianapolis (Roudebush), Indianapolis, Indiana, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.